Author Archive: Tracy Cooley

Tracy Cooley

Tracy serves as the Director of Events Communications and handles all communications for BIO’s events and emerging company policy issues. She loves blogging and podcasting on all things biotech and believes in the great potential of the industry, looking for every opportunity to spread the message far and wide. Nearly everyone in her family is a golfer, and as such, she has what many people have called a “natural” swing. Sometimes she even hits the ball. Tracy just finished her ninth marathon, and has nearly mastered the skill of one-foot-in-front-of-the-other (usually, sometimes the laces get in the way). The joy of her life is her five-year-old daughter Josephine.

Latest Posts

Patient groups eager to speed cures

The 8th Annual BIO Investor Forum is attracting patient advocacy and venture philanthropy groups from across the country, who are interested in partnering to speed cures. Some of the participating organizations include: Fast Forward CureDuchenne The Leukemia & Lymphoma Society MDA Venture Philanthropy Epilepsy Therapy Project The Parkinson’s Institute These groups understand how critical it is for patient advocates, venture philanthropists, and biotech companies to work together to speed treatments and cures.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags:

Plexxikon Announces PLX4032 Phase I Clinical Trial Results

Plexxikon Inc. reports positive clinical data from a Phase 1 extension study of PLX4032 (RG7204) in metastatic melanoma patients. PLX4032 targets the BRAFV600E mutation that occurs in about 50 percent of melanomas and about eight percent of solid tumors. Tumor shrinkage has been observed in nearly all of the currently evaluable patients in the extension study, reflecting a 70 percent response rate. Plexxikon and Roche are co-developing PLX4032 under their 2006 license and collaboration agreement.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags:

Peptimmune Collaborates with Walter Reed on Dengue Virus Vaccine

Peptimmune, Inc. has formed a collaboration with the Walter Reed Army Institute of Research and Naval Medical Research Center for the development of Dengue vaccines and point-of-care diagnostics. The goal of the R&D project is to evaluate the company’s Directed Expansion of Epitope Permutations (DEEP) technology to potentially design DENV-specific peptide copolymers. The results of this effort have the potential to provide insights into dengue immunity and advance the development of a protective vaccine.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags:

Idera Pharmaceuticals Phase 2 Results for Renal Cell Carcinoma Therapy

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced final data results from a clinical trial evaluating IMO-2055, a monotherapy in patients with Renal Cell Carcinoma. Progression-free survival medians for treatment-naïve patients were 4.5 months at 0.16 mg/kg/week and 1.9 months at 0.64 mg/kg/week.  The most common adverse events included fatigue, nausea, chills, headache, and pyrexia.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags:

Cleveland BioLabs Receives Additional Funding for Radiation Project

Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced an additional $2.3 million in funding for a $13.3 million contract with the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (DHHS) for the development of Radiation Countermeasure Protectan CBLB502. In addition, BARDA increased the first milestone-based option from $4.0 million to $6.3 million, increasing the total contract value including all milestone-based options from $13.3 million to $15.6 million over the Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: